The stock has shot up this past week on 2 whispers, IMHO. (1) The CEO is enthusiastic about the Company given the success of the lower number of stemcells that have produced a remarkable result. No numbers or qualities out there, yet. He's simply smiling like the proverbial Cheshire Cat and disappearing with the huge smile hanging around! That's call building confidence.
Secondly, the whispers are about how many they will be injecting at a time for the rest of the Phase I/II trial. Recall they were talking about the cohorts specifically arranged by increasing dosages of stemcells. I'm hearing that they might inject a whole cohort at a time which would collapse the time to completion radically. Further, this has changed the landscape as to how quickly ACTC.OB can get to their next level of Trials... AND HOW LONG SUCH A TRIAL WOULD LAST!!! This is the hidden driver of value. This is the BIG KAHUNA in my humble opinion...
Therefore, to my fellow investors, if you have heard or read differently, please correct this analysis. We don't want unbridled optimism hear if it isn't merited. But, if you concur with this cocktail napkin commentary, please let me know.
Why is the above 2 whispers important beyond what I've already stated? You see the General Biotech Investor Market has been obsessed with the GERN complete retreat from their trials involving the nervous system. IMO, the Street was thinking that ACTC.OB would follow suit. As this breath of optimism continues to grow, the Company will continue to gain in value and in share price.
The Market also gave a thumbnail expectation as to when ACTC would be re-valued. It would be after painfully long trials. The whispers about the injection timing has the street aflutter.
Good luck.
AI
